Mortality in systemic sclerosis: an international meta-analysis of individual patient data.

[1]  A. Hoffman,et al.  Treatment of diabetic ketoacidosis: should mode of insulin administration dictate use of intensive care facilities? , 2004, The American journal of medicine.

[2]  G. Umpierrez,et al.  Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. , 2004, The American journal of medicine.

[3]  A. Kitabchi,et al.  Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. , 2004, Diabetes care.

[4]  A. Kitabchi,et al.  Hyperglycemic crises in diabetes. , 2004, Diabetes care.

[5]  Stephen W Lagakos,et al.  Clinical trials and rare diseases. , 2003, The New England journal of medicine.

[6]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[7]  A. Balasubramanyam,et al.  Improved outcomes in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  J. Vaqué,et al.  Mortality and prognostic factors in Spanish patients with systemic sclerosis. , 2003, Rheumatology.

[9]  Richard W. Martin,et al.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. , 2002, Arthritis and rheumatism.

[10]  M. Mayes,et al.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. , 2002, Blood.

[11]  John P A Ioannidis,et al.  Commentary: meta-analysis of individual participants' data in genetic epidemiology. , 2002, American journal of epidemiology.

[12]  S. Bombardieri,et al.  Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.

[13]  L. Stewart,et al.  To IPD or not to IPD? , 2002, Evaluation & the health professions.

[14]  É. Rich,et al.  Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival , 2002, Medicine.

[15]  J. Ioannidis,et al.  Design and quality considerations for randomized controlled trials in systemic sclerosis. , 2002, Arthritis and rheumatism.

[16]  T. Medsger,et al.  Improvement in skin thickening in systemic sclerosis associated with improved survival. , 2001, Arthritis and rheumatism.

[17]  F. Wollheim,et al.  Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale , 2001, Annals of the rheumatic diseases.

[18]  A. Wiik,et al.  Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. , 2001, The Journal of rheumatology.

[19]  Douglas G Altman,et al.  Systematic reviews of evaluations of prognostic variables , 2001, BMJ : British Medical Journal.

[20]  J. Reveille,et al.  Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. , 2001, Seminars in arthritis and rheumatism.

[21]  J. Ioannidis,et al.  Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. , 2001, Journal of clinical epidemiology.

[22]  A. Kitabchi,et al.  Management of hyperglycemic crises in patients with diabetes. , 2001, Diabetes care.

[23]  Richard W. Martin,et al.  Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. , 2000, Arthritis and rheumatism.

[24]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[25]  U. Dafni,et al.  Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele , 2000, Annals of the rheumatic diseases.

[26]  A. Silman,et al.  Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. , 1999, Arthritis and rheumatism.

[27]  A. Silman,et al.  A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.

[28]  F. Locatelli,et al.  Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. , 1999, Arthritis and rheumatism.

[29]  F. Arnett,et al.  Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. , 1999, Arthritis and rheumatism.

[30]  R. Hesselstrand,et al.  Mortality and causes of death in a Swedish series of systemic sclerosis patients , 1998, Annals of the rheumatic diseases.

[31]  S. Ullman,et al.  Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma) , 1998, British journal of rheumatology.

[32]  Christopher H Schmid,et al.  Summing up evidence: one answer is not always enough , 1998, The Lancet.

[33]  Furst De,et al.  Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. , 1997 .

[34]  M. Mayes,et al.  Racial differences in scleroderma among women in Michigan. , 1997, Arthritis and rheumatism.

[35]  W. Tierney,et al.  Diabetic Ketoacidosis Charges Relative to Medical Charges of Adult Patients With Type I Diabetes , 1997, Diabetes Care.

[36]  A. Silman,et al.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. , 1996, British journal of rheumatology.

[37]  J G Thornton,et al.  Clinical trials and rare diseases: a way out of a conundrum , 1995, BMJ.

[38]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[39]  L. Stewart,et al.  From science to practice. Meta-analyses using individual patient data are needed. , 1995 .

[40]  P. Lachenbruch,et al.  Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. , 1995, Arthritis and rheumatism.

[41]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[42]  P. Lachenbruch,et al.  Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. , 1994, Chest.

[43]  D. Bloch,et al.  Predictors of survival in systemic sclerosis (scleroderma). , 1991, Arthritis and rheumatism.

[44]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[45]  W R Mayr,et al.  Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. , 1983, Diabetes care.

[46]  K. Rothman,et al.  Epidemiologic Analysis with a Programmable Calculator , 1982 .

[47]  T. M. Hayes,et al.  Human insulin: study of safety and efficacy in man. , 1981, British medical journal.

[48]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[49]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[50]  A. Kitabchi,et al.  Diabetic ketoacidosis: low-dose insulin therapy by various routes. , 1977, The New England journal of medicine.